IBDEI0IX ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8515,1,4,0)
;;=4^C92.41
;;^UTILITY(U,$J,358.3,8515,2)
;;=^5001802
;;^UTILITY(U,$J,358.3,8516,0)
;;=C92.40^^39^401^20
;;^UTILITY(U,$J,358.3,8516,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8516,1,3,0)
;;=3^Acute Promyelocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,8516,1,4,0)
;;=4^C92.40
;;^UTILITY(U,$J,358.3,8516,2)
;;=^5001801
;;^UTILITY(U,$J,358.3,8517,0)
;;=D56.0^^39^401^21
;;^UTILITY(U,$J,358.3,8517,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8517,1,3,0)
;;=3^Alpha Thalassemia
;;^UTILITY(U,$J,358.3,8517,1,4,0)
;;=4^D56.0
;;^UTILITY(U,$J,358.3,8517,2)
;;=^340494
;;^UTILITY(U,$J,358.3,8518,0)
;;=D63.1^^39^401^23
;;^UTILITY(U,$J,358.3,8518,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8518,1,3,0)
;;=3^Anemia in Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,8518,1,4,0)
;;=4^D63.1
;;^UTILITY(U,$J,358.3,8518,2)
;;=^332908
;;^UTILITY(U,$J,358.3,8519,0)
;;=D63.0^^39^401^24
;;^UTILITY(U,$J,358.3,8519,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8519,1,3,0)
;;=3^Anemia in Neoplastic Disease
;;^UTILITY(U,$J,358.3,8519,1,4,0)
;;=4^D63.0
;;^UTILITY(U,$J,358.3,8519,2)
;;=^321978
;;^UTILITY(U,$J,358.3,8520,0)
;;=D63.8^^39^401^22
;;^UTILITY(U,$J,358.3,8520,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8520,1,3,0)
;;=3^Anemia in Chronic Diseases Classified Elsewhere
;;^UTILITY(U,$J,358.3,8520,1,4,0)
;;=4^D63.8
;;^UTILITY(U,$J,358.3,8520,2)
;;=^5002343
;;^UTILITY(U,$J,358.3,8521,0)
;;=C22.3^^39^401^27
;;^UTILITY(U,$J,358.3,8521,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8521,1,3,0)
;;=3^Angiosarcoma of Liver
;;^UTILITY(U,$J,358.3,8521,1,4,0)
;;=4^C22.3
;;^UTILITY(U,$J,358.3,8521,2)
;;=^5000936
;;^UTILITY(U,$J,358.3,8522,0)
;;=D61.9^^39^401^28
;;^UTILITY(U,$J,358.3,8522,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8522,1,3,0)
;;=3^Aplastic Anemia,Unspec
;;^UTILITY(U,$J,358.3,8522,1,4,0)
;;=4^D61.9
;;^UTILITY(U,$J,358.3,8522,2)
;;=^5002342
;;^UTILITY(U,$J,358.3,8523,0)
;;=D56.1^^39^401^34
;;^UTILITY(U,$J,358.3,8523,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8523,1,3,0)
;;=3^Beta Thalassemia
;;^UTILITY(U,$J,358.3,8523,1,4,0)
;;=4^D56.1
;;^UTILITY(U,$J,358.3,8523,2)
;;=^340495
;;^UTILITY(U,$J,358.3,8524,0)
;;=C83.79^^39^401^36
;;^UTILITY(U,$J,358.3,8524,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8524,1,3,0)
;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8524,1,4,0)
;;=4^C83.79
;;^UTILITY(U,$J,358.3,8524,2)
;;=^5001600
;;^UTILITY(U,$J,358.3,8525,0)
;;=C83.70^^39^401^37
;;^UTILITY(U,$J,358.3,8525,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8525,1,3,0)
;;=3^Burkitt Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,8525,1,4,0)
;;=4^C83.70
;;^UTILITY(U,$J,358.3,8525,2)
;;=^5001591
;;^UTILITY(U,$J,358.3,8526,0)
;;=D09.0^^39^401^44
;;^UTILITY(U,$J,358.3,8526,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8526,1,3,0)
;;=3^Carcinoma in Situ of Bladder
;;^UTILITY(U,$J,358.3,8526,1,4,0)
;;=4^D09.0
;;^UTILITY(U,$J,358.3,8526,2)
;;=^267742
;;^UTILITY(U,$J,358.3,8527,0)
;;=D06.9^^39^401^45
;;^UTILITY(U,$J,358.3,8527,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8527,1,3,0)
;;=3^Carcinoma in Situ of Cervix
;;^UTILITY(U,$J,358.3,8527,1,4,0)
;;=4^D06.9
;;^UTILITY(U,$J,358.3,8527,2)
;;=^5001941
;;^UTILITY(U,$J,358.3,8528,0)
;;=D06.0^^39^401^47
;;^UTILITY(U,$J,358.3,8528,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0IX 3768 printed Sep 23, 2025@19:25:34 Page 2
IBDEI0IX ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8515,1,4,0)
+2 ;;=4^C92.41
+3 ;;^UTILITY(U,$J,358.3,8515,2)
+4 ;;=^5001802
+5 ;;^UTILITY(U,$J,358.3,8516,0)
+6 ;;=C92.40^^39^401^20
+7 ;;^UTILITY(U,$J,358.3,8516,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,8516,1,3,0)
+10 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
+11 ;;^UTILITY(U,$J,358.3,8516,1,4,0)
+12 ;;=4^C92.40
+13 ;;^UTILITY(U,$J,358.3,8516,2)
+14 ;;=^5001801
+15 ;;^UTILITY(U,$J,358.3,8517,0)
+16 ;;=D56.0^^39^401^21
+17 ;;^UTILITY(U,$J,358.3,8517,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,8517,1,3,0)
+20 ;;=3^Alpha Thalassemia
+21 ;;^UTILITY(U,$J,358.3,8517,1,4,0)
+22 ;;=4^D56.0
+23 ;;^UTILITY(U,$J,358.3,8517,2)
+24 ;;=^340494
+25 ;;^UTILITY(U,$J,358.3,8518,0)
+26 ;;=D63.1^^39^401^23
+27 ;;^UTILITY(U,$J,358.3,8518,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,8518,1,3,0)
+30 ;;=3^Anemia in Chronic Kidney Disease
+31 ;;^UTILITY(U,$J,358.3,8518,1,4,0)
+32 ;;=4^D63.1
+33 ;;^UTILITY(U,$J,358.3,8518,2)
+34 ;;=^332908
+35 ;;^UTILITY(U,$J,358.3,8519,0)
+36 ;;=D63.0^^39^401^24
+37 ;;^UTILITY(U,$J,358.3,8519,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,8519,1,3,0)
+40 ;;=3^Anemia in Neoplastic Disease
+41 ;;^UTILITY(U,$J,358.3,8519,1,4,0)
+42 ;;=4^D63.0
+43 ;;^UTILITY(U,$J,358.3,8519,2)
+44 ;;=^321978
+45 ;;^UTILITY(U,$J,358.3,8520,0)
+46 ;;=D63.8^^39^401^22
+47 ;;^UTILITY(U,$J,358.3,8520,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,8520,1,3,0)
+50 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
+51 ;;^UTILITY(U,$J,358.3,8520,1,4,0)
+52 ;;=4^D63.8
+53 ;;^UTILITY(U,$J,358.3,8520,2)
+54 ;;=^5002343
+55 ;;^UTILITY(U,$J,358.3,8521,0)
+56 ;;=C22.3^^39^401^27
+57 ;;^UTILITY(U,$J,358.3,8521,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,8521,1,3,0)
+60 ;;=3^Angiosarcoma of Liver
+61 ;;^UTILITY(U,$J,358.3,8521,1,4,0)
+62 ;;=4^C22.3
+63 ;;^UTILITY(U,$J,358.3,8521,2)
+64 ;;=^5000936
+65 ;;^UTILITY(U,$J,358.3,8522,0)
+66 ;;=D61.9^^39^401^28
+67 ;;^UTILITY(U,$J,358.3,8522,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,8522,1,3,0)
+70 ;;=3^Aplastic Anemia,Unspec
+71 ;;^UTILITY(U,$J,358.3,8522,1,4,0)
+72 ;;=4^D61.9
+73 ;;^UTILITY(U,$J,358.3,8522,2)
+74 ;;=^5002342
+75 ;;^UTILITY(U,$J,358.3,8523,0)
+76 ;;=D56.1^^39^401^34
+77 ;;^UTILITY(U,$J,358.3,8523,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,8523,1,3,0)
+80 ;;=3^Beta Thalassemia
+81 ;;^UTILITY(U,$J,358.3,8523,1,4,0)
+82 ;;=4^D56.1
+83 ;;^UTILITY(U,$J,358.3,8523,2)
+84 ;;=^340495
+85 ;;^UTILITY(U,$J,358.3,8524,0)
+86 ;;=C83.79^^39^401^36
+87 ;;^UTILITY(U,$J,358.3,8524,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,8524,1,3,0)
+90 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
+91 ;;^UTILITY(U,$J,358.3,8524,1,4,0)
+92 ;;=4^C83.79
+93 ;;^UTILITY(U,$J,358.3,8524,2)
+94 ;;=^5001600
+95 ;;^UTILITY(U,$J,358.3,8525,0)
+96 ;;=C83.70^^39^401^37
+97 ;;^UTILITY(U,$J,358.3,8525,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,8525,1,3,0)
+100 ;;=3^Burkitt Lymphoma,Unspec Site
+101 ;;^UTILITY(U,$J,358.3,8525,1,4,0)
+102 ;;=4^C83.70
+103 ;;^UTILITY(U,$J,358.3,8525,2)
+104 ;;=^5001591
+105 ;;^UTILITY(U,$J,358.3,8526,0)
+106 ;;=D09.0^^39^401^44
+107 ;;^UTILITY(U,$J,358.3,8526,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,8526,1,3,0)
+110 ;;=3^Carcinoma in Situ of Bladder
+111 ;;^UTILITY(U,$J,358.3,8526,1,4,0)
+112 ;;=4^D09.0
+113 ;;^UTILITY(U,$J,358.3,8526,2)
+114 ;;=^267742
+115 ;;^UTILITY(U,$J,358.3,8527,0)
+116 ;;=D06.9^^39^401^45
+117 ;;^UTILITY(U,$J,358.3,8527,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,8527,1,3,0)
+120 ;;=3^Carcinoma in Situ of Cervix
+121 ;;^UTILITY(U,$J,358.3,8527,1,4,0)
+122 ;;=4^D06.9
+123 ;;^UTILITY(U,$J,358.3,8527,2)
+124 ;;=^5001941
+125 ;;^UTILITY(U,$J,358.3,8528,0)
+126 ;;=D06.0^^39^401^47
+127 ;;^UTILITY(U,$J,358.3,8528,1,0)
+128 ;;=^358.31IA^4^2
